Rocket One Inc., formerly Hoth Therapeutics, does not currently carry a meaningful analyst price target. Major data providers list no one-year target estimate for the shares, reflecting a micro-cap with a market capitalization of only about $9.5 million and no established institutional research coverage. For that reason, this article does not rely on an analyst consensus.
Instead, the $1.00 price objective is drawn from an identifiable, publicly discussed threshold: Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a $1.00 minimum bid price. Rocket One regained compliance in June 2026 after its shares closed at or above $1.00 for 10 consecutive business days, but the company disclosed a new deficiency notice dated August 6, 2026, giving it 180 calendar days — until February 2, 2027 — to regain compliance or face potential delisting, possibly via a reverse stock split.
This makes $1.00 a realistic, well-defined benchmark for the stock forecast discussion: it is a concrete level the company itself is monitoring, it sits well above the current price, and it is not an arbitrary headline figure. It is a regulatory milestone rather than a valuation-based stock price target, and it should not be mistaken for an analyst's view of intrinsic value.
The shares closed at about $0.38 on November 10, 2026, near the bottom of a 52-week range of roughly $0.37 to $2.45. Reaching $1.00 would require a rise of about 163%, a very large move that would effectively more than double the current market value. The stock trades as a penny stock, with a market capitalization near $9.5 million and no positive earnings, so its price is driven largely by news flow, financing activity, and retail sentiment rather than conventional valuation.
The company has been active in announcements. It reached an agreement with NASA to advance space AI technology, signed a patent license with the U.S. Air Force, joined the Seagate partner program, launched a drone-swarm threat emulation platform, and reported positive Phase 2a efficacy results for its HT-001 drug candidate. These headlines have periodically lifted the shares, but the stock has repeatedly faded back toward the $0.37–$0.40 area, suggesting that event-driven rallies have not yet translated into a sustained move toward $1.00.
The most direct catalyst is regulatory: management has a clear incentive to keep the shares above $1.00 to preserve the Nasdaq listing, and it has indicated it may consider options including a reverse stock split to restore compliance. Beyond that, the company's repositioning toward radiation-tolerant, ultra-low-power nanomagnetic AI chip technology targets a genuinely growing orbital and defense computing market, and the string of government and industry agreements provides some early validation of its strategy.
The legacy biotech pipeline also retains optional value. The positive HT-001 Phase 2a readout and plans to pursue Phase 3 could, if partnered or financed separately, support sentiment. Finally, the shares' extreme volatility means that even modest, confirmed progress — a new contract, a prototype milestone, or a favorable financing — has historically produced outsized percentage moves in a stock with a float this small.
The obstacles are substantial. The company is pre-revenue in its space and AI business and loss-making, with a trailing twelve-month net loss of roughly $13.3 million and limited cash of about $7.9 million. Its nanomagnetic chip technology has not yet been fabricated as an integrated device, validated in space, or qualified for any commercial or government program.
Financing is another headwind. Rocket One has expanded its at-the-market equity offering program, which can dilute existing shareholders and has historically pressured micro-cap share prices. There is also genuine delisting risk: if the bid price does not return to $1.00 for 10 consecutive business days by the February 2, 2027 deadline, the company may need a reverse split, which often coincides with further weakness. Finally, competition from far larger, better-funded semiconductor and defense contractors remains a structural challenge.
The shares are testing a durable support zone near $0.37, the 52-week low, while $0.50 has acted as resistance during the October-to-November pullback. Above that, $1.00 is the key psychological and regulatory level: the stock spent several days above it in mid-2026 before falling back. A sustained close above $1.00 would mark both a technical and a listing-compliance milestone, whereas a break below $0.37 would open the door to new lows and intensify delisting pressure.
Because there is no analyst coverage, there is no standard 12-month research horizon to reference. The most relevant near-term date is the February 2, 2027 Nasdaq compliance deadline. Investors should monitor the bid price's ability to hold above $1.00 for 10 consecutive business days, the pace of cash burn and any new equity issuance, progress on the nanomagnetic chip and NASA, Air Force, and Seagate relationships, and further data or partnership news on the HT-001 program. Quarterly results and any reverse-split or compliance announcements will be the most direct signals on the path toward $1.00.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like RKTO, where sentiment can shift quickly, these signals can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual chart review. Traders can use the tool to track RKTO alongside a broader watchlist and stay ahead of shifts in momentum.
The question of whether Rocket One can reach $1.00 is ultimately a question about Nasdaq listing compliance as much as business fundamentals. The $1.00 objective is not an analyst-derived price target — there is no meaningful analyst coverage — but a regulatory threshold the company has a concrete deadline to reclaim. A 163% move is very large, and the path is complicated by losses, dilution, and pre-revenue technology. At the same time, the stock's small float, its recent government and industry agreements, and management's strong incentive to protect the listing mean sharp moves are possible in either direction. Investors should watch the cash position, new equity issuance, the compliance deadline, and the pace of technology and biotech milestones rather than treat $1.00 as a guaranteed outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, RKTO has been loosely correlated with CLRB. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if RKTO jumps, then CLRB could also see price increases.
| Ticker / NAME | Correlation To RKTO | 1D Price Change % | ||
|---|---|---|---|---|
| RKTO | 100% | -3.87% | ||
| CLRB - RKTO | 44% Loosely correlated | -4.69% | ||
| LYEL - RKTO | 39% Loosely correlated | +8.63% | ||
| ORIC - RKTO | 36% Loosely correlated | -3.47% | ||
| RXRX - RKTO | 34% Loosely correlated | -6.70% | ||
| NTAP - RKTO | 33% Loosely correlated | -0.05% | ||
More | ||||
| Ticker / NAME | Correlation To RKTO | 1D Price Change % |
|---|---|---|
| RKTO | 100% | -3.87% |
| Computer Communications industry (166 stocks) | 8% Poorly correlated | +2.58% |